Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
35.27
-0.35 (-0.98%)
At close: Apr 14, 2026, 4:00 PM EDT
35.40
+0.13 (0.37%)
Pre-market: Apr 15, 2026, 6:08 AM EDT
Tyra Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts that cover Tyra Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $46.78, which forecasts a 32.63% increase in the stock price over the next year. The lowest target is $30 and the highest is $59.
Price Target: $46.78 (+32.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tyra Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 3 | 4 | 4 | 5 |
| Buy | 3 | 2 | 3 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 6 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +41.76% | Apr 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $56 | Buy | Maintains | $42 → $56 | +58.78% | Mar 20, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $45 | Strong Buy | Maintains | $30 → $45 | +27.59% | Feb 17, 2026 |
| Wedbush | Wedbush | Buy Maintains $37 → $53 | Buy | Maintains | $37 → $53 | +50.27% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.47
from -2.01
EPS Next Year
-2.68
from -2.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.15 | -2.14 | |||
| Avg | -2.47 | -2.68 | |||
| Low | -2.61 | -2.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.